Creating a serum bank to find early markers for pancreatic cancer
SERum-bank for PANcreatic Cancer
This study is trying to collect blood samples from people with pancreatic cancer to see if certain markers can help catch the disease earlier.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Saint-Etienne and 1 other locations) |
| Trial ID | NCT04374175 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a serum library from patients with adenocarcinoma to evaluate various serum biomarkers, including adiponectin, for the early diagnosis of pancreatic cancer. The study will collect blood samples from participants at different stages of the disease, focusing on those who are starting treatment. By comparing these samples to a control group, researchers hope to identify potential blood markers that could facilitate earlier detection of pancreatic cancer, which is often diagnosed at advanced stages. The ultimate goal is to improve diagnostic methods and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with documented adenocarcinoma, regardless of stage, who are starting treatment.
Not a fit: Patients with acute renal failure, advanced cirrhosis, or those with other synchronous cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of pancreatic cancer, significantly improving treatment outcomes.
How similar studies have performed: Other studies have explored serum biomarkers for cancer detection, but the specific approach of this study is novel in the context of pancreatic cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
ADENOCARCINOMA GROUP Inclusion Criteria: * Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. * At the start of treatment (before surgery / 1st course of chemotherapy) * Age ≥ 18 years * Patient affiliated or entitled to a social security system Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years * Language barrier CONTROL GROUP Inclusion Criteria: * Age ≥ 40 years * Patient affiliated or entitled to a social security system * Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years
Where this trial is running
Saint-Etienne and 1 other locations
- CHU Saint-Etienne — Saint-Etienne, France (Recruiting)
- Institut Cancérologique Lucien Newirth (ICLN) — Saint-Priest-en-Jarez, France (Recruiting)
Study contacts
- Principal investigator: Nicolas WILLIET, MD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Nicolas WILLIET, MD
- Email: nicolas.williet@chu-st-etienne.fr
- Phone: (0)477829029
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.